Skip to main content

Table 1 Demographic and clinical characteristics at inclusion.

From: A French multicenter randomised trial comparing two dose-regimens of prothrombin complex concentrates in urgent anticoagulation reversal

 

4-factor PCC regimen

 
 

25 IU/kg

(n = 29)

40 IU/kg

(n = 30)

P value

Age, years

77.7 ± 9.4

75.2 ± 11.1

0.265

Male gender

19 (65.5)

23 (76.7)

0.344

Body weight, kg

76.9 ± 17.6

76.7 ± 13.5

0.779

Medical history

  

NS

   Hypertension

18 (62.1)

21 (70.0)

 

   Atrial fibrillation

18 (62.1)

18 (60.0)

 

   Previous ischemic stroke

3 (10.3)

4 (13.3)

 

   Diabetes mellitus

8 (27.6)

7 (23.3)

 

   Hypercholesterolemia

3 (10.3)

5 (16.7)

 

Blood pressure, mm Hg

   

   SBP

154 ± 23.4

162 ± 32.7

0.359

   DBP

84.1 ± 14.0

86.2 ± 18.3

0.524

Blood glucose, mmol/L

7.7 ± 3.1

7.6 ± 2.4

0.946

Onset to diagnosis, hrs

29.4 ± 51.6

45.8 ± 82.0

0.213

INR

2.9 ± 1.1

3.2 ± 1.9

0.660

GCS

13.3 ± 2.7

13.2 ± 2.8

0.846

Type of intracranial haemorrhage

  

0.862

   Intracerebral haemorrhage

18 (64.3)

18 (62.1)

 

   Acute subdural haemorrhage

10 (35.7)

11 (37.9)

 

Haematoma volume, cm 3

23.8 ± 18.5

16.5 ± 18.9

0.438

  1. Results are expressed as n (%) or mean ± SD. NS, not significant. GCS, Glasgow Coma Scale; INR, international normalised ratio; PCC, prothrombin complex concentrate.